regulatory
confidence high
sentiment neutral
materiality 0.05
Galecto corrects Series C Preferred Stock authorization from 43,855 to 43,882 shares
Damora Therapeutics, Inc.
- Filed Certificate of Correction on Dec 5, 2025 to fix inadvertent error in Series C Preferred Stock designation.
- Authorized shares revised to 43,882 from incorrectly stated 43,855; no other terms changed.
- Amendment amends 8-K originally filed Nov 10, 2025; restated certificate attached as Exhibit 3.3.